Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)UnknownNCT03085368
What this trial is testing

Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

Who this might be right for
HER2-positive Breast Cancer
Peking Union Medical College Hospital 482
Testing effectiveness (Phase 2)Active Not RecruitingNCT06068985
What this trial is testing

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Latin American Cooperative Oncology Group 63
Early research (Phase 1)UnknownNCT01304797
What this trial is testing

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Merrimack Pharmaceuticals 75
Large-scale testing (Phase 3)Study completedNCT03425656
What this trial is testing

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Who this might be right for
Malignant Neoplasm of Breast
AryoGen Pharmed Co. 108
Not applicableNot Yet RecruitingNCT07132502
What this trial is testing

Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 24
Testing effectiveness (Phase 2)Looking for participantsNCT07407920
What this trial is testing

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2-Positive Breast Carcinoma+1 more
M.D. Anderson Cancer Center 120
Large-scale testing (Phase 3)Active Not RecruitingNCT00070564
What this trial is testing

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 3,294
Testing effectiveness (Phase 2)Looking for participantsNCT04983121
What this trial is testing

Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients

Who this might be right for
Breast Neoplasms
Shengjing Hospital 30
Early research (Phase 1)Study completedNCT01921335
What this trial is testing

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Who this might be right for
Brain Metastases From HER2 and Breast CancerAdvanced HER2-positive Breast Cancer
Dana-Farber Cancer Institute 41
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Large-scale testing (Phase 3)UnknownNCT05871918
What this trial is testing

A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

Who this might be right for
HER-2 Positive Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 832
Testing effectiveness (Phase 2)Active Not RecruitingNCT03747120
What this trial is testing

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

Who this might be right for
HER2-positive Breast CancerBreast Cancer
University of Texas Southwestern Medical Center 138
Not applicableStudy completedNCT01840306
What this trial is testing

Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Who this might be right for
Breast CancerHER2 Positive Breast CancerHER2 Negative Breast Cancer
Cancer Trials Ireland 330
Large-scale testing (Phase 3)Not Yet RecruitingNCT07213206
What this trial is testing

CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 1,500
Testing effectiveness (Phase 2)UnknownNCT04197687
What this trial is testing

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Who this might be right for
Breast AdenocarcinomaStage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7+5 more
Academic and Community Cancer Research United 480
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287
What this trial is testing

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Who this might be right for
SHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more
Tianjin Medical University Cancer Institute and Hospital 30
Large-scale testing (Phase 3)Study completedNCT05338723
What this trial is testing

Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

Who this might be right for
Chemotherapy-induced CardiotoxicityBreast Cancer
Tanta University 50
Not applicableLooking for participantsNCT06700369
What this trial is testing

De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 519
Testing effectiveness (Phase 2)Study completedNCT00875979
What this trial is testing

Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 67
Large-scale testing (Phase 3)Active Not RecruitingNCT05426486
What this trial is testing

ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Who this might be right for
HER2-positive Breast Cancer
Caigang Liu 136
Next Page